OIFE		SHEET I OF I	
Form PTO-1 49 JUN 1 7 2005 U.S. DEPARTMENT OF COMMERCE (Rev. ) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO	SERIAL NO. 10/777,543	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANTS Harold M. Bates		
(Use several sheets if necessary)	FILING DATE February 12, 2004	GROUP 1646	

### **U.S. PATENT DOCUMENTS**

Examiner Initial	Cite No.	U.S. Patent Document Number	Date	Name	Class .	Subclass	Filing Date If Appropriate
							·
				•			

#### FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Trans	lation
						Yes	No
			1				

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

June 8, 2005 International Search Repor	t and Written Opinion for PCT/US05/023	27.
Armitage & Colton (editors), Encyclope	dia of Biostatistics, volume 5, pages 3628-	3629 and 3838-3842 (1998).
/David Venci/	DATE CONSIDERED	01/22/2007
	Armitage & Colton (editors), Encyclope	June 8, 2005 International Search Report and Written Opinion for PCT/US05/023  Armitage & Colton (editors), Encyclopedia of Biostatistics, volume 5, pages 3628-  /David Venci/  DATE CONSIDERED

not considered. Include copy of this form with next communication to applicant.

	U.S. I PATE ORMATION DISCLOSU BY APPLICAL (Use several sheets if I	C15043/174944 10/777,543  APPLICANT Harold M. Bates						
TO PROPERTY.			U.S. PATENT D	OCUMENTS:	****	GROU	P: 1646	
Examiner Initial	Document Number	Date		Name	Class	Subclass	Filing Date If Appropriate	
			FO	REIGN FATENT D	OCUME	NTS		
	Document Number	Date		Country	Class	Subclass	Translation	1
				<del>\</del>				
	ОТНЕВ	DOCUME	ENTS (Including A	uthor, Title, Date, Pertin	ent Pages, E	tc.)		
	"Autoantibod	ies to Oxid	ized Low Densi	nson AH, Collins P ty Lipoprotein: the F viabetic Medicine (	Relationsh	ip to Low D	ensity Lipopro	tein
				e status of lipoprote 123, pages 285-29		onary disea	se patients."	
	Monoclonal	Autoantiboo	dies to Epitopes	echer UP, Powell Ho of Oxidized Lipopro (1996), volume 98,	oteins fro	<b>Q</b> Apolipopr		
	C, Marks JD. Evolution of	"Isolation the Comple	of Picomolar Alementary Determ	all KW, Merritt H, Yi ffinity Anti-c-erbB-2 nining Regions in th lume 263, pages 5	Single-ch ne Center	nain Fv by M	folecular	
				nteractions: Their Q omatography (1989	), volume	492, pages	377 430.	е
EXAMINED  Examiner: Initial in not considered. In	/David Ve if citation considered, whe clude copy of this form wi	ther or not cita	ation is in conforma	DATE CONSIDERED nce with MPER609; Drawnt.		1/22/200 gh citation if no		and

Form PTO-1449 (Rev. )			T OF COMMERCE DEMARK OFFICE	ATTY. DOCKET NO.:	APPLICATION NO.: 10/777,543				
	ORMATION DISCLOSUI BY APPLICAN (Use several sheets if r	ST.	ENT .	C15043/174944		10////,3	·. /		
	30,5	•		APPLICANT Harold M. Bates					
AUG 2 0	106 B			FILING DATE Februar	y 12, 2004	GROU	P: 1646		
FIRAT & TRACE	appet 1		U.S. PATENT D	OCUMENTS			/		
Examiner Initial	Document Number	Date		Name	Class S	ubclass	Filing Date If Appropriat	e	
	+		<u> </u>				<u> </u>		
	+								
							· · ·		
· .									
		·							
			X					-	
		<u>                                     </u>	FO	REIGN PATENT D	OCUMENTS	3		1	
	Document Number	Date	c	Country	Class S	ubclass	Translati	on	
	4-173096	6/1992	JA	PAN		, <del></del>	English Abstract		
				- · · · · · · · · · · · · · · · · · · ·	. 1				
		/				<del> </del>			
	OTHER	DOCUME	ENTS (Including A	uthor, Title, Date, Pertine	nt Pages, E.c.)				
	11./	•				<b>\</b>			
	+/		· <del> · · · · · · · · · · · · · · · · ·</del>			+			
							<u> </u>		
EXAMINER	/ /Dav	id Venc:	i/ I	DATE CONSIDERED	01/	22/200	7		
Examiner: Initial not considered. In	if citation considered, whet clude copy of this form wit	her or not cita	ation is in conformar unication to applican	nce with MPEP 609; Dravit.	w line through c	itation if n	ot in conforman	ce and	
							1	\ .	
								1	
								1	

ALE .	PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT  BY APPLICANT								
1104 8 6 JOBE W				APPLICANT Harole					
				FILING DATE Feb	ruary 12, 2004	GROL	JP: 646		
RAD		L L	J.S. PATENT D	OCUMENTS	<del></del>	/			
Examiner Initial	Document Number	Date		Name	Class	Subolass	Filing Date If Appropriate		
·				·		/			
	. \								
. ,				/					
						·			
				-					
			X						
			FO	REIGN PATENT	DOCUME	NTS			
	Document Number	Date		Country	Class	Subclass	Translation		
			/	$\overline{}$					
					$\overline{}$				
···	OTHER	DOCUME	NTS (Including A	uthor, Title, Date, Per	rtinent Pages.	Etc.)	<del></del>		
				brochure (photoco		<del>\</del>	ember 2004.		
	Johnston N, J Coronary Arte 1; 97(5): 640-6	ry Disease B	ly The Use Of No	bahn A, Wallentin ew Lipid And Lipop	L. *Improve protein Bioma	d Identification	on Of Patents With Cardiol. 2006 Mar		
	Johnston N, J	emberg T, La	agerqvist B, Sieg atients With Uns	bahn A, Wallentin table Coronary Art	L. "Oxidized ery Disease,	Low-Density Int J Cardio	Lipoprotein As A		
EXAMINER	/D	d Venci	7	DATE CONSIDEREI		1/22/200			

Form PTO-1449  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  PATENT AND TRADEMARK OFFICE  BY APPLICANT  (Use several sheets if necessary)  NOV 1 0 7005								
A TOTAL	Luxuo (			FILING DATE February 12, 2004 GROUP: 1646				
R.W.A.	2 Harden	<del> </del>	U.S. PATENT D	OCUMENTS				<del></del>
Examiner Initial	Document Number	Date		Name	Class	Subclass	Filing Dat	
					/			
		ackslash						
					1			
				/				
			X				,	
			FO	REIGN PATENT D	OCUMEN	NTS	<u> </u>	
	Document Number	Date		Country	Class	Subclass	Trans	lation
					ļ			
						·		
		/			1			
	OZUE	DOCUME	NTS (L. L. L.			<u></u>		<del> </del>
	T			uthor, Title, Date, Pertine		<del>\                                    </del>	: 479-484.	
	Gesari M, Krit Newman AB,	chevsky SB, Pahor M. "L	, Nicklas BJ, Peni ipoprotein peroxi	ninx BW, Holvoet P, I dation and mobility lir 2005 Oct 10; 165(18)	Koh-Banerjonitation: re	ee P. Summ	ings SR, H	
	strong predict	or for acute	coronary heart di	oewel H, Koenig W. 'sease events in appa 2; 112(5): 651-657 (E	rently heal	thy, middle-a		
XAMUVER	/David	Venci /				1 /00 /00	7	<b>,</b>
	f citation considered, whe			DATE CONSIDERED		1/22/200	<del></del>	+

Com PTO-1	449	U.S	. DEPARTMENT OF	COMMERCE	ATTY. DOCKET NO.		SERIAL	NO.		
(Rev. )	_	. PAT	ENT AND TRADEN	MARK OFFICE	C15043/0174944		10/777	10/777,543		
ON	POR PAR	TION DISCLO	OSURE STATEM	IENT	APPLICANT Harold M. Bates					
JUH 1	8 2004	se several sheet	s if necessary)		FILING DATE GROUP					
					February 12, 2004		Not Ye	t Assigned		
PAD!	MARKU				U.S. PATENT DOC	CUMENTS	. /	/		
Examiner Initial	Cite No.	U.S. Putent Document Number	Date		Name	Class	Subclass	Filing Da If Approp		
		. \								
_			<b>\</b>			$\perp /$	<u> </u>		····	
*						/				
					/	/	<u> </u>			
	<u>                                     </u>		1	FO	REIGN PATENT I	OCUMEN	TS	1		
		Document Number	Date		Country	Class	Subclass	Trans	slation	
				X				Yes	No	
. •		•			$\overline{}$	•				
				/	$\overline{}$		<u> </u>		-	
					<del></del>					
	l	OTI	IER DOCUMEN	TS (Including A	uthor, Title, Date, Pertin	ent Pages, Etc	e.)			
		Holvoet P, Krito Syndrome, Circu	hevsky SB, Tracy RJ	P, Mertens A, R L, And Risk of N	ubin SM, Butler J, Goo Ayocardial Infarction In abetes. 2004; 53(4): 10	odpaster B, H n Well-Funct	arris TB. "Th			
		Sigurdardottir V Factors of The N 2002; 257(5): 44	letabolic Syndrome	e J. "Circulating And LDL Size i	Oxidized Low-Densit n Clinically Healthy 58	y Lipoproteil -Year-Old M	(LDL) Is Ass fee (AIR Stud	sociated Wi y)." <i>J Inter</i>	th Risk in Med.	
							$\overline{}$	<del></del>		
									<u>-</u> -	
XAMINER		/D	avid Venci/		DATE CONSIDERED	01/22	2/2007	+		
xaminer: In	nitial if c	itation considered, of this form	whether or not citation	n is in conforman	ce with MPEP 609; Dra	w line through	h citation if not	in conform	ace and	

orm PTO-1449 U.S. DEPARTMENT OF COMMERCE ATTY. DOCKET NO. SERIAL NO. PATENT AND TRADEMARK OFFICE Not Yet Assigned C015043/0174944 **APPLICANT** INFORMATION DISCLOSURE STATEMENT BY APPLICANT Harold M. Bates GROUP **FILING DATE** Use several sheets if necessary) Filed Concurrently herewith Not X et Assigned

#### **U.S. PATENT DOCUMENTS**

Examiner Initial	Cite No.	U.S. Patent Document Number	Date	. Name	Class	Subclass	Filing Date If Appropriate
		5,024,829	V1991	Berger et al.			
		5,026,537	6/1991	Daddona et al.			
		5,046,499	9/1991	Berger			,
		5,120,834	6/1992	Gargan et al.		_	
		5,196,324	3/1993	Bumol et al.			
		5,223,410	6/1993	Cargan et al.			
		5,362,649	11/1994	Schwertner			
		5,380,667	1/1995	Schwertner			
		5,396,886	3/1995	Cuypers			
		5,453,359	9/1995	Gargan et al.			
		5,487,892	1/1996	Gaggan			·
		5,597,726	1/1997	Bumol et al.			
		5,604,105	2/1997	Jackowski			
		5,658,729	8/1997	Hayden et al.			
		5,690,103	11/1997	Groth et al.			
		5,710,008	1/1998	Jackowski			
		5,731,208	3/1998	Henicke			
		5,756,067	5/1998	Redgrave et al.			
		6,040,147	3/2000	Ridker et al.			
		6,309,888	10/2001	Holvoet			
		2003/0100486	5/2003	Ridker		1	
		2003/0152566	8/2003	Schonbeck et al.			
	/						

EXAMINER

/David Venci/

DATE CONSIDERED

01/22/200

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and pot considered. Include copy of this form with next communication to applicant.

RS1129593

r								SHI	EET 2 OF 18	
Form PTO-1449 (Rev. )				ATTY. DOCKET NO. C015043/0174944				SERIAL NO. NotYet Assigned		
INFOR	APPLICANT Harold M. Bates									
	(Use several sheets if necessary)					FILING DATE Filed Concurrently Herewith				
		FO	REIGN PATENT	r DOCUMI	ENTS					
	Document Number	Date		Country		Class	Subclass	Tran	slation	
	EP 0 327 418 A1	8/1989	ЕРО					Yes	No	
	EP 0 433 088 B1	6/1307	EPO							
	EP 0 484 863 A1	5/1992	EPO							
	WO 94/23302	10/1994	PCT		$\overline{}$			-		
					7					

WO 98/59248 12/1998 WO 00/14548 3/2000 Kokai 8-304395 11/1996 JP Х Kokai 9-5323 10/1997 JP EXAMINER DATE CONSIDERED /David Venci/ 01/22/2007

Form PTO-1449 (Rev. )	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. C015043/0174944	SERIAL NO. No Yet Assigned			
INFÖRM	ATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Harold M. Bates				
	(Use several sheets if necessary)	FILING DATE GROUP Filed Concurrently Herewith Notifet Assigned				
	OTHER DOCUMENTS (Including A	Author, Title, Date, Pertinent Pages, Etc.)				
	Adams JE, 3d, Bodor GS, Da Ladenson JH, Jaffe AS. "C High Specificity For Cardi 88(1): 101-106.	ardiac Troponin I./ A	Marker With			
	American Biogenetic Science (1995).	es Inc. 1995 Annual R	eport. 24 pages			
	tic Tests: A ages. Paisley					
	American Biogenetic Science venture announced by Ameri Gull Laboratories, Inc." N	es, Inc., "Renal dial can Biogenetic Science ews Release (9/26/96)	ysis joint es, Inc. and			
·	American Biogenetic Scienc Corporation, "New Buy Reco pages.)	es, Inc. Jesup & Lam mmendation dated Marc	ont Securities h 28, 1996" (12			
	Antman EM, Tanasijevic MJ, Cannon CP, Fischer GK, Fun Braunwald E. "Cardiac-Spe The Risk Of Mortality In P Syndromes." N. Eng. J. Med	g AY) Thompson C, Wyb cific Troponin I Leve	enga D, ls To Predict			
	AtheroGenics, Inc. Printou (WWW.ATHEROGENICS.COM). H and "In The News" sections	ome page and "Technol	ogy Platform" June 8, 1998).			
Aviram M, Maor I. "Phospholipase D-Modified Low Density Lipoprotein Is Taken Up By Macrophages At Increased Rate. Possible Role For Phosphatidic Acid." J. Clin. Invest. 1993 91: 1742-1952.						
	Berliner JA, Heinecke JW. In Atherogenesis," Free Ra 20(5): 707-727					
	1					
EXAMINER	/David Venci/	DATE CONSIDERED 01	/22/2007			
Supplier Laboration	distinct and design and all the second and all the					

corn PTO-1449 ATTY. DOCKET NO. U.S. DEPARTMENT OF COMMERCE SERIAL NO. PATENT AND TRADEMARK OFFICE No Yet Assigned C015043/0174944 **APPLICANT** INFORMATION DISCLOSURE STATEMENT BY APPLICANT Harold M. Bates GROUB FILING DATE (Use several sheets if necessary) Filed Concurrently Herewith Not Net Assigned OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Boyd A Gown AM, Wolfbauer G, Chait A. "Direkt Evidence For A Protein Recognized By A Monoclonal Antibody Against Oxidatively Modified LDL In Atherosclerotic Lesions From A Watanabe Ayperlipidemic Rabbit." Am. J. Pathol. 1989 November;  $N_{5}(5)$ : 815-825. Brody, JE. "Hunt For Heart Disease Tracks A New Suspect." The New York Times. 3 pages (Jan. 6/2004). Brown MS, Goldstain JL. "Lipoprote in Metabolism In The Macrophage: Implications For Cholesterol Deposition In Atherosclerosis." Annu. Review Biochem. 1983; 52: 223-261. Cartier R, Dagenais F Hollmarn C, Cambron H, Buluran J. "Chronic Exposure To Cyclosperin Affects Endothelial And Smooth Muscle Reactivity In The Rat Aorta." Ann. Thorac. Surg. 1994; 58: 789-794. Chapelle JP. "How Should We proceed When A Myocardial Infarction Is Suspected," Acta Clinica Belgica 1984; 39(6): 393-395. Chen CH, Nguyen HH / Weilbaecher Q, Luo S, Gotto Jr. AM, Henry PD. "Basic Fibroblast Growth Factor Reverses Atherosclerotic Impairment Of Human Coronary Angiogenesis-Like Responses In Vitro." Atherosclerosis 1995; 116: 261-268. Chin JH, Azhar S, Hoffman BB. "Inactivation Of Endothelial Derived Relaxing Factor By Oxidized Lipoproteins." J. Clin. Invest. 19\$2; 89: 10-18. Cockcroft DW, Gault MH. "Prediction of creatinine clearance from serum creatinine." Nephron 1976; 16: 31\41 Crist SJ, Dunn JM, Rose ML, Barbir M, Yacoub MF "Antiendothelial Antibodies After Heart Transplantation: The Accelerating Factor In Transplant-Associated Corolary Artery Disease?" J. Heart Lung Transplant. 1994; 13(1, Part 1): 81-92. **EXAMINED DATE CONSIDERED** /David Venci/ 01/22/2007 Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Korm PTO-1449 (Rev. )	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. C015043/0174944	SERIAL NO. No Yet Assigned
INFOR	MATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Harold M. Bates	
	(Use several sheets if necessary)	FILING DATE Filed Concurrently Herewith	GROUP Not Jet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	Declerck PJ, Mombaerts P, Holvoet P, De Mol M Collen D. "Fibrinolytic Response And Fibrin Fragment D Dimer Levels In Patients With Deep Vein Thrombosis." Thromb. Haemost. 1987; 58(4): 1024-1029.		
	Degoulet P, Legrain M, Reach I, Aime F, Devries C, Rojas P, Jacobs C. "Mortality Risk Factors In Patients Treated By Chronic Hemodialysis." Nephron 1982: 31: 103-110.		
	Esterbauer H, Jungens G, Quehenberger Q, Koller E. "Autooxidation Of Human Low Density Lipoprotein: Loss Of Polyunsaturated Fatty Acids And Vitamin E And Generation Of Aldehydes." J. Lipid Res. 1987; 28: 495-509.		
	Farber HW, Barnett HF. "Differences In Prostaglandin Metabolism In Cultured Aortic And Pulmonary Arterial Endothelial Cells Exposed To Acute And Chronic Hypoxia." Circ. Res. 1991; 68(5): 1416-1457.		
	Fogelman MA, Shechter Y, Seager J, Hokom M, Child JS, Edwards PA. "Malondialdehyde Alteration Of Low Density Lipoproteins Leads To Cholesteryl Ester Accumulation In Human Monocyte-Macrophages." Proc. Natl. Acad. Sci. USA 1980; 77(4): 2214-2218.		
·	Folcik VA, Nivar-Aristy RA, Krajewski LP, Cathcart MK. "Lipoxygenase Contributes To The Oxidation Of Lipids In Human Atherosclerotic Plaques." J. Clin. Invest. 1995; 96: 504-510.		
	Friedman JA, Dwyer JT. "Hyperhomocysteinemia As A Risk Factor For Cardiovascular Disease In Patients Undergoing Hemodialysis." Nutr. Rev. 1995; 53(7): 197-201		
	Galle J, Bengen J, Schollmeyer P, Wanner C. Oxidized Lipoprotein(A) Inhibits Endothelium-Dependent Dilation: Prevention By High Density Lipoprotein." Eur. J. Pharmacol. 1994; 265: 111-115.		
	<i>X</i>		
EXAMINER	/David Venci/	DATE CONSIDERED 0	01/22/200
Examiner: Initial not considered. In	if citation considered, whether or not citation is in conformanuclude copy of this form with next communication to applican	ce with MPEP 609; Draw line through citat t.	ion if not in conformance and

Form PTO-1449 SERIAL NO. U.S. DEPARTMENT OF COMMERCE ATTY. DOCKET NO. PATENT AND TRADEMARK OFFICE Nd Yet Assigned C015043/0174944 **APPLICANT** INFORMATION DISCLOSURE STATEMENT BY APPLICANT Harold M. Bates **FILING DATE** (Use several sheets if necessary) GROUD Filed Concurrently Herewith Not Yet Assigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Ec.)

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Ec.)				
	Low Density Lipoproteins S	e Of The Endothelium." Eur. Heart J.			
	Gerrity RG. "The Role Of Transition Of Blood-Borne Lesions." Am. J. Pathol.	The Monocyte In Atherogenesis. I. Monocytes Into Foam Cells In Fatty 1981; 103(2): 181-190.			
	Grattan MT, Moreno-Cabral Shumway NE. "Cytomegalovin Cardiac Allograft Rejection Assoc. 1989; 261(24): 3561	CE, Starnes VA, Oyer PE, Stinson EB, rus Infection Is Associated With on And Atherosclerosis." J. Am. Med. 3566.			
	Receptor-Mediated Recognit	Edwards PA. "Specificity Of ion Of Malondialdehyde-Modified Low oc. Watl. Acad. Sci USA. 1982; 79:			
	Haberland ME, Olch CL, Fogelman AM. "Role Of Lysines In Mediating Interaction Of Modified Low Density Lipoproteins With The Scavenger Receptor Of Human Monocyte Macrophages." J. Biol. Chem. 1984; 259(18): 11305-11311.				
	Hamm WC, Goldmann BU, Heeschen C, Kreymann G, Berger J, Meinertz T. "Emergency Room Triage Of Ratients With Acute Chest Pain By Means Of Rapid Testing For Cardiac Troponin T Or Troponin I." N. Eng. J. Med. 1997; 337(23): 1648-1653.				
	Hamm Wo, Goldmann BU, Heeschen C, Kreymann G, Berger J, Meinertz T. "Emergency Room Triage Of Patients With Acute Chest Pain By Means Of Rapid Testing For Cardiac Troponin T Or Troponin I." N. Eng. J. Med. 1997; 337(23): 1648-1653. Letters concerning same and authors' reply, published in N. Eng. J. Med. 1998; 338(18): 1314-1315.				
EXAMINER	/David Venci/	DATE CONSIDERED 01/22/2007			
		<del></del>			

# Form PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

APPLICANT Harold M. Bates

ATTY. DOCKET NO.

C015043/0174944 ·

FILING DATE

Filed Concurrently Herewith

Not Yet Assigned

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	"Generation, Characterizat Of Monoclonal Antibodies S Modified ApoB-Containing S	Rabl H, Ghassempur I, Jurgens G. tion, And Histochemical Application Selectively Recognizing Oxidatively Serum Lipoproteins." C. Biol. 1995; 17(5): 704-713.		
	Wall, Volume VI (Harwood A	). Immune Functions of the Vessel Academic Publishers 1996). Chapter "Autoimmunity To Oxidized 171.		
		JH. "The Distribution And Chemical fugally Separated Lipoproteins In rest. 1955; 34: 1345-1353.		
	Heery JM, Kozak M, Stafforini DM, Jones DA, Zimmerman GA, McIntyre TM, Prescott SM. Oxidatively Modified LDL Contains Phospholipids With Platelet-Activating Factor-Like Activity And Stimulates The Growth Of Smooth Muscle Cells."  J. Clin. Invest. 1995; 6: 2322-2330.			
	Hirschfield GM, Pepys MB. cardiovascular disease: ne J Med. 2003 Nov; 96(11): 7	w insights from an old molecule." Q		
	Hlatky MA. "Evaluation Of Chest Pain In The Emergency Department." N. Eng. J. Med. 1997; 337(23): 1687-1689.			
	Hoff HF, O'Neill J. "Lesion-Derived Dow Density Lipoprotein And Oxidized Low Density Lipoprotein Share A Lability For Aggregation, Leading To Enhanced Macrophage Degradation." Arterioscler. Thromb. 1991; 11(5): 1209-1222.			
·	Hoff HF, O'Neill J, Chisolm III GM, Cole TB, Quehenberger O, Esterbauer H, Jurgens G. "Modification Of Low Density Lipoprotein With 4-Hydroxynonenal Induces Uptake By Macrophages." Arteriosclerosis 1989; 9(4): 538-549.			
EXAMINER	/David Venci/	DATE CONSIDERED 01/22/2007		

Coronary Atherosclerosis In Rabbits." Arterioscler. Thromb. Vasc. Biol. 1997; 17(11) 2/376-2382. "Oxidized Lipoproteins In Holvoet P, Collen D. Atherosclerosis And Thrømbosis." FASEB J. 1994; 8: 1279-1284. Holvoet P, Collen D. "Thrombosis And Atherosclerosis." Curr. Opinion Lipidol. 199/1; 8: 320-388. Holvoet P, Perez Q, Zhao Z, Brouwers E, Bernar H, Collen D. "Malondialdehyde Modified Low Dens ty Lipoproteins In Patients With Atherosclerotic Disease." J. Chin. Invest. 1995; 95: 2611-2619. Holvoet P, Donck J, Landeloos M, Brouwers E, Luijtens K, Arnout J, Zesaffre E, Vanrenterghem Y, Collen D. "Correlation Between Oxidized Low Density Lipoproteins and Von Willebrand Factor In Chronic Renal Failure." Thromb. Naemost. 1996; 76(5): 663-669. Holvoet P, Van Kleemput J, Collen D, Vanhaecke "Correlation Between Oxidized Low Density Lipoproteins And Coronary Artery Disease In Heart Transplant Patients." Mostract published in Final Programme of 66th Congless of the European Atherosclerosis Society, Florence (Italy), July 13-14, 1996; Abstract Book, page 47.

**EXAMINER** DATE CONSIDERED /David Venci/ 01/22/2007

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**DATE CONSIDERED** 

01/22/2007

/David Venci/

EXAMINE

SHEET 10 OF 18 orm PTO-1449 ATTY. DOCKET NO. U.S. DEPARTMENT OF COMMERCE SERIAL NO. PATENT AND TRADEMARK OFFICE Nd Yet Assigned C015043/0174944 **APPLICANT** INFORMATION DISCLOSURE STATEMENT **BY APPLICANT** Harold M. Bates **FILING DATE** GROUP (Use several sheets if necessary) Filed Concurrently Herewith Not Yet Assigned OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	To a state of the	radio, rine, bate, retrinent rages, bic.)	
	H, Reitz BA, Hutchins GM. Heart Transplant Recipient	Baumbgartner WA, Augustine SM, Ren "Accelerated Arteriosclerosis In s Is Associated With A T-aelialitis." Am J. Pathol. 1990;	
	associated with subclinica	Circulating oxidized LDL is atherosclerosis development and R Study)." Arterioscler Thromb Vasc 62-1167.	
	T, Takano T. "A Monoclona Lipoprotein Recognizes Foa Complex Formation Of Oxidi	saki H. Kimura J. Yoshida Y. Imanaka al Antibody Against Oxidized am Cells In Atherosclerotic Lesions: zee Phosphatidylcholines And Chem. 1994; 269(21): 15274-15279.	
	Itabe H, Yamamoto H, Imanaka T, Shimamura K, Uchiyama H, Kimura J, Sanaka T, Hata Y, Takano T. "Sensitive Detection Of Oxidatively Modified Low Density Lipoprotein Using A Monoclonal Antibody." J. Lipid Res. 1996; 37: 45-53.		
	Juckett MB, Balla J, Balla G, Jessurun J, Jacob HS, Vercellotti GM. Ferritin Protects Endothelial Cells From Oxidized Low Density Lipoprotein In Vitro." Am. J. Pathol. 1995; 147(3): 782-789.		
	Kaplan R, Aynedjian HS, Schlondorff D, Bank N. "Renal Vasoconstriction Caused By Short-Term Cholesterol Feeding Is Corrected By Thromboxane Antagonist Or Probucol." J. Clin. Invest. 1990; 86: 1707-1714.  Keane WF, Mulcahy WS, Kasiske BL, Kim Y, O'Donnell MP. "Hyperlipidemia And Progressive Renal Disease." Kidney Int. 1991, 39(Suppl.): S41-S48.		
	Kolata, G. "A New Generation Of Tests To Determine Heart Trouble." New York Times News Service. 7 pages (Nov. 26, 1995).		
EXAMINER	/David Venci/	DATE CONSIDERED 01/22/2007	

			311001 11 01 18
Form PTO-1449 (Rev. )	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. C015043/0174944	SERIAL NO. NotYet Assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Harold M. Bates	
	(Use several sheets if necessary)	FILING DATE Filed Concurrently Herewith	GROUP Not Yet Assigned
	OTHER DOCUMENTS (Including A	uthor, Title, Date, Pertinent Pages, Etc.)	
	Koskinen P, Lemstrom K, Bru P. "Acute Cytomegalovirus Inflammation (Endothelialit A Possible Linkage With En Am. J. Pathol. 1994; 144(	Infection Induces X tis) In The Allograft nhanced Allograft Art	Subendothelial Vascular Wall.
	Kotani K, Maekawa M, Kanno T, Kondo A, Zoda N, Manabe M. "Distribution Of Immunoreactive Malondialdehyde-Modified Low-Density Lipoprotein In Human Serum." Biochimica et Biophysica Acta 1994; 1215. 121-125.		
	Lee TH, Goldman L. "Serum Enzymes In The Diagnosis Of Acute Myocardial Infarction, Annals of Internal Medicine 1986; 105: 221-223.		
	Libby P, Salomon RN, Payne DD, Schoen FJ, Pober JS. "Functions Of Vascular Wall Cells Related To Development Of Transplantation-Associated Coronary Arteriosclerosis." Transplant. Proc. 1989; 21(4): 3677-3684.		
	Lynch SM, Morrow JD, Robert Non-Cyclooxygenase-Derived Plasma And Low Density Lipo In Vitro." J. Clip. Invest	Prostanoids ( $F_2$ -Isopoprotein Exposed To C	rostanes) In Oxidative Stress
	Mabile L, Fitoussi G, Perio Negre-Salvayre A. "Alpha- Early Intracellular Events By Oxidized Low Density Lin Cells." Free Radic. Biol. I	Pocopherol And Trolox (TBARS And Calcium R poproteins In Culture	Block The Lises) Elicited d Endothelial
	Major AS, Dove DE, Ishiguro H, Su YR, Brown AM, Liu L, Carter KJ, Linton MF, Fazio S. "Increased Cholesterol Efflux In Apolipoprotein AI (ApoAI)-Producing Macrophages As A Mechanism For Reduced Atherosclerosis In ApoAI((-/-)) mice."  Arterioscler Thromb Vasc Biol. 2001 Nov; 21(11) 1790-1795.		
	Menschikowski M, Kasper M, Stockinger H, Jaross W. "Se In Human Atherosclerotic PI 173-181.	ecretory Group II Pho	sph <b>o</b> lipase A2
EXAMINER	/David Venci/	DATE CONSIDERED 01/2	2/2007
Examiner: Initial if	citation considered, whether or not citation is in conforman ude copy of this form with next communication to applican	ice with MPEP 609; Draw line through cita	tion if not in conformance and

EXAMINER

/David Venci/

Arteriosclerosis 1990; 10(3): 325-335.

**DATE CONSIDERED** 

01/22/2007

		Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. "Prospective Study Of C-Reactive Protein And The Risk Of Future Cardiovascular Events In Stable And Unstable Angina." Circulation 1998; 98:731-733.
		Rose EA, Smith CR, Petrossian GA, Barr ML, Reemtsma K. "Humoral Immune Responses After Cardiac Transplantation: Correlation With Fatal Rejection And Graft Atherosclerosis." Surgery 1989; 108(2): 203-208.
		Rosenfeld ME, Palinski W, Yla-Herttuala, Butler S, Witztum JL. "Distribution Of Oxidation Specific Lipid-Protein Adducts And Apolipoprotein B In Atherosclerotic Lesions Of Varying Severity From WHHL Rabbits." Arteriosclerosis 1990; 10(3): 336-349.
		Ross R. "The Pathogenesis Of Atherosclerosis: A Perspective For The 1990s." Nature 1998; 362: 801-809.
	•	Salonen JT, Yla-Herttvala S, Yamamoto R, Butler S, Korpela H, Salonen R, Nyyssonen K, Palinski W, Witztum JL. "Autoantibody Against Oxidised LDL And Progression Of Carotid Atherosclerosis." Lancet 1992; 339 (8798): 883-887.
		Sasavage N. "Predicting Coronary Artery Disease. New Markers Could Identify Patients At Risk." Clin. Lab. News March 1998; pages 6-7.
		Savenkova ML, Mueller DM, Heinecke JW. "Tyrosyl Radical Generated By Myeloperoxidase Is A Physiological Catalyst For The Initiation Of Lipid Peroxidation In Low Density Lipoprotein." J. Biol. Chem. 1994; 269(32): 20394-20400.
•		Schaffner T, Taylor K, Bartucci EJ, Fischer-Dzoga K, Beeson JH, Glagov S, Wissler RW. "Arterial Foam Cells With Distinctive Immunomorphologic And Histochemical Features Of Macrophages." Am. J. Pathol. 1980; 100(1): 57-80.

EXAMINER /David Venci/ DATE CONSIDERED 01/22/2007

#### Form PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. ) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. C015043/0174944

**APPLICANT** Harold M. Bates

INFORMATION DISCLOSURE STATEMENT **BY APPLICANT** 

(Use several sheets if necessary)

**FILING DATE** 

Filed Concurrently Herewith

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	Bavendiek U, Robbie L, Gar Low-Density Lipoprotein Au	co N, Reynolds RS, Horton DB, nz P, Kinlay S, Libby P. "Oxidized agments And 3-Hydroxy-3-Reductase Inhibitors Limit CD40 And Vascular Cells. Circulation 2002;		
	Shacter E. Quantification Oxidation In Biological San Nov; 32(3-4): 307-26.	on And Significance Of Protein amples." Drug Metab Rev. 2000 Aug-		
	Shultz EK. "Clinical Interprocedures." Chapter 14 in Chemistry. Burtis CA, Ash W.B.Saunders Company. Page	erpretation Of Laboratory In Teitz, Fundamentals of Clinical awood ER (eds.). 4th edition 1996. ges 192-199.		
	Schulz T, Schiffl H, Scheitze R, Hrboticky N, Lorenz R. "Preserved Antioxidative Defense Of Lipoproteins In Renal Failure And During Hemodialysis." Am. J. Kidney Dis. 1995; 25(4): 564-571.			
	Selwyn AP, Kinlay S, Libby P, Ganz P. "Atherogenic Lipids, Vascular Dysfunction, And Clinical Signs Of Ischemic Heart Disease." Circulation 1997; 95(1): 5-7.			
	Sparrow CP, Olszewski J. "Cellular Oxidative Modification Of Low Density Lipoprotein Does Not Require Lipoxygenases."  Proc. Nat. Acad. Sci. USA 1992; 89: 128-131.			
	Sparrow CP, Partharasathy S, Leake DS, Steinberg D. "Enzymatic Modification Of Low Density Lipoprotein By Purified Lipoxygenase Plus Phospholipase-A2 Mimic Cell-Mediated Oxidative Modification." J. Lipid Res. 1988; 29: 745-753.			
	Steinberg D, Witztum JL. "Lipoproteins And Atherogenesis: Current Concepts." J. Am. Med. Assoc. 1990; 264(23): 3047-3052.			
EXAMINER	/David Venci/	DATE CONSIDERED 01/22/2007		

EXAMINER /David Venci/ DATE CONSIDERED 01/22/2007